[go: up one dir, main page]

BR0206501A - Cruzipain and other cysteine protease inhibitors - Google Patents

Cruzipain and other cysteine protease inhibitors

Info

Publication number
BR0206501A
BR0206501A BR0206501-0A BR0206501A BR0206501A BR 0206501 A BR0206501 A BR 0206501A BR 0206501 A BR0206501 A BR 0206501A BR 0206501 A BR0206501 A BR 0206501A
Authority
BR
Brazil
Prior art keywords
cruzipain
cysteine protease
protease inhibitors
inhibitors
general formula
Prior art date
Application number
BR0206501-0A
Other languages
Portuguese (pt)
Inventor
Martin Quibell
Original Assignee
Amura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0101179A external-priority patent/GB0101179D0/en
Application filed by Amura Therapeutics Ltd filed Critical Amura Therapeutics Ltd
Publication of BR0206501A publication Critical patent/BR0206501A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"INIBIDORES DE CRUZIPAìNA E OUTRAS CISTEìNA PROTEASES". A presente invenção refere-se a compostos da fórmula geral (I) ou fórmula geral (II) em que R^ 1^, P~ 1~, P~ 2~, Q, Y, (X)~ O~, (W)~ n~, (V)~ m~, Z e U são como definidos no relatório descritivo, são inibidores de cruzipaína e outros inibidores de cisteína protease e são úteis como agentes terapêuticos, por exemplo, na doença de Chagas, ou para validar compostos de alvo terapêutico."CRUZIPAIN INHIBITORS AND OTHER CYSTEIN PROTEASES". The present invention relates to compounds of the general formula (I) or the general formula (II) wherein R 1, R 1, P 2, Q, Y, (X) O, (W) ) ~ n ~, (V) ~ m ~, Z and U are as defined in the specification, are cruzipain inhibitors and other cysteine protease inhibitors and are useful as therapeutic agents, for example in Chagas disease, or for validating therapeutic target compounds.

BR0206501-0A 2001-01-17 2002-01-17 Cruzipain and other cysteine protease inhibitors BR0206501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0101179A GB0101179D0 (en) 2001-01-17 2001-01-17 Biologically active compounds
US27535901P 2001-03-13 2001-03-13
PCT/GB2002/000184 WO2002057270A1 (en) 2001-01-17 2002-01-17 Inhibitors of cruzipain and other cysteine proteases

Publications (1)

Publication Number Publication Date
BR0206501A true BR0206501A (en) 2004-01-13

Family

ID=26245571

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206501-0A BR0206501A (en) 2001-01-17 2002-01-17 Cruzipain and other cysteine protease inhibitors

Country Status (21)

Country Link
US (2) US7425562B2 (en)
EP (1) EP1362052B1 (en)
JP (1) JP4608183B2 (en)
KR (1) KR100860067B1 (en)
CN (1) CN1269822C (en)
AT (1) ATE356130T1 (en)
AU (1) AU2002219397B2 (en)
BR (1) BR0206501A (en)
CA (1) CA2436462C (en)
CY (1) CY1106640T1 (en)
DE (1) DE60218633T2 (en)
DK (1) DK1362052T3 (en)
ES (1) ES2281516T3 (en)
HK (1) HK1060729A1 (en)
IL (2) IL156774A0 (en)
MX (1) MXPA03006224A (en)
NO (1) NO328208B1 (en)
NZ (1) NZ526913A (en)
PT (1) PT1362052E (en)
RU (1) RU2329266C2 (en)
WO (1) WO2002057270A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156577A0 (en) 2000-12-22 2004-01-04 Axys Pharm Inc Selective cathepsin s inhibitors and pharmaceutical compositions containing the same
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
CA2460125A1 (en) 2001-09-14 2003-03-27 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
JP2005514353A (en) 2001-11-14 2005-05-19 アベンティス・ファーマスーティカルズ・インコーポレイテツド Oligopeptides as cathepsin S inhibitors and compositions containing them
ATE424401T1 (en) * 2002-07-16 2009-03-15 Amura Therapeutics Ltd PYRROL DERIVATIVES AS INHIBITORS OF CYSTEIN PROTEASES
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
ES2341869T3 (en) 2004-01-08 2010-06-29 Medivir Aktiebolag CISTEIN PROTEASA INHIBITORS.
JP2005350417A (en) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd Method for producing pyrrolidine derivative using reductive etherification method
NZ561681A (en) * 2005-03-21 2011-01-28 Virobay Inc Alpha ketoamide compounds as cysteine protease inhibitors
GB0513839D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0513840D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614037D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614073D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
WO2008114054A1 (en) * 2007-03-19 2008-09-25 Medivir Ab Protease inhibitors
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
WO2009087379A2 (en) * 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
GB0804702D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0804701D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US9409880B2 (en) 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
EP2891492B1 (en) 2012-08-30 2022-11-09 The University of Tokyo Endoparasite control agent
CN106279188A (en) * 2016-07-21 2017-01-04 青岛科技大学 A kind of preparation method of furane derivative also [2,3 b] azole derivatives

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652574A (en) * 1970-04-01 1972-03-28 Abbott Lab Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof
DZ2285A1 (en) 1996-08-08 2002-12-25 Smithkline Beecham Corp Cysteine protease inhibitors.
JP2000517319A (en) 1996-08-28 2000-12-26 スミスクライン・ビーチャム・コーポレイション Inhibitors of cysteine protease
SI0951466T1 (en) 1996-12-23 2009-10-31 Elan Pharm Inc Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
AR013079A1 (en) * 1997-05-06 2000-12-13 Smithkline Beecham Corp SUBSTITUTED DERIVATIVES OF TETRAHIDROFURANO-3-ONAS, TETRAHIDROPIRANO-3- ONAS AND TETRAHIDROTIOFEN-3-ONAS, A PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION OF A MEDICINAL PRODUCT USEFUL AS INTERMEDIATE PROTEIN INHIBITORS
MA26618A1 (en) 1998-04-09 2004-12-20 Smithkline Beecham Corp PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MALARIA
CO5150165A1 (en) 1998-11-13 2002-04-29 Smithkline Beecham Plc PROTEASE INHIBITORS: KATEPSIN K TYPE
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
CA2428863A1 (en) 2000-11-17 2002-05-23 Medivir Uk Limited Cysteine protease inhibitors
IL156577A0 (en) 2000-12-22 2004-01-04 Axys Pharm Inc Selective cathepsin s inhibitors and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
ES2281516T3 (en) 2007-10-01
EP1362052A1 (en) 2003-11-19
US20040138250A1 (en) 2004-07-15
PT1362052E (en) 2007-04-30
ATE356130T1 (en) 2007-03-15
NO20033220D0 (en) 2003-07-16
KR100860067B1 (en) 2008-09-24
NO20033220L (en) 2003-09-17
US20090247471A1 (en) 2009-10-01
HK1060729A1 (en) 2004-08-20
CN1486320A (en) 2004-03-31
MXPA03006224A (en) 2004-10-15
JP4608183B2 (en) 2011-01-05
DE60218633D1 (en) 2007-04-19
DE60218633T2 (en) 2008-02-21
CA2436462A1 (en) 2002-07-25
RU2003125270A (en) 2005-02-20
CY1106640T1 (en) 2012-01-25
RU2329266C2 (en) 2008-07-20
AU2002219397B2 (en) 2008-02-14
NO328208B1 (en) 2010-01-11
WO2002057270A1 (en) 2002-07-25
KR20030075161A (en) 2003-09-22
EP1362052B1 (en) 2007-03-07
IL156774A0 (en) 2004-02-08
CA2436462C (en) 2011-07-05
US7425562B2 (en) 2008-09-16
JP2004518674A (en) 2004-06-24
IL156774A (en) 2008-08-07
CN1269822C (en) 2006-08-16
DK1362052T3 (en) 2007-07-09
NZ526913A (en) 2004-12-24

Similar Documents

Publication Publication Date Title
BR0206501A (en) Cruzipain and other cysteine protease inhibitors
BR0209127A (en) compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
BR0309556A (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0109165A (en) Cholemic polyps treatment method
BR0308211A (en) Coumarins Useful as Biomarkers
BR0209129A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds.
BR0015254A (en) N-substituted carbamoyloxyalkyl azole derivatives
BR0305426A (en) Hsv ns5b polymerase inhibitor compounds as well as pharmaceutical composition comprising the same
PL406680A1 (en) Tyrosine kinase inhibitors
SE0201976D0 (en) Novel compounds
BRPI0416902A (en) hepatitis c virus ns3 / ns4a serine protease inhibitors
NO20035603D0 (en) Fluoropyrrolidines as dipeptidyl peptidase inhibitors
BR0214519A (en) Factor xa and other serine protease inhibitors involved in the coagulation cascade
BRPI0419305B8 (en) p38 inhibitor compounds, pharmaceutical compositions comprising the same and uses of said compounds in the preparation of medicines
BRPI0410995A (en) n-alkynyl-2- (substituted aryloxy) alkylthioamide derivatives as fungicides
BR0305258A (en) Hcv ns5b polymerase inhibitors
BR0207278A (en) Phthalazinone-piperidine derivatives as pde4 inhibitors
BR0013081A (en) Metalloproteinase-inhibiting pyrimidine-2,4,6-triones
BR0114252A (en) Nitrosodiphenylamine derivatives
BR0212535A (en) Compounds and compositions as cathepsin inhibitors
BR0209128A (en) Compounds, pharmaceutical compositions, methods for treating pain, methods for modulating a pharmacological response and uses of compounds
BR9916680A (en) Derivatives of 3,3-biarylpiperidine and 2,2-biarylmorpholine
BR0309386A (en) Triaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinases inhibitors
BR0215016A (en) Antiviral Pyridoquinoxalines
ECSP034561A (en) PIPERAZINE BRIDGE DERIVATIVES

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: GRUENENTHAL GMBH (DE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.